Why the study?
Clinical and mechanistic studies have reported contradictory results regarding whether anti-hypertensive drugs are associated with cancer risks, creating uncertainties for patients.
Are anti-hypertensive drugs associated with an increased risk of incident cancer in patients with hypertension?
Are anti-hypertensive drugs associated with an increased risk of incident cancer in patients with hypertension?
Answers are grounded in this paper and cite their sources.
This review highlights the ongoing controversy and contradictory evidence regarding the potential link between long-term anti-hypertensive drug use and cancer risk.
Hypertension is the prevailing independent risk factor for cardiovascular disease worldwide. Anti-hypertensive drugs are the common and effective cure for lowering blood pressure in patients with hypertension. However, some large-scale clinical studies have pointed out that long-term ingestion of some oral anti-hypertensive drugs was associated with risks of incident cancer and the survival time. In contrast, other studies argue that anti-hypertensive drugs are not related to the occurrence of cancer, even as a complementary therapy of tumor treatment. To resolve the dispute, numerous recent mechanistic studies using animal models have tried to find the causal link between cancer and different anti-hypertensive drugs. However, the results were often contradictory. Such uncertainties have taken a toll on hypertensive patients. In this review, we will summarize advances of longitudinal studies in the association between anti-hypertensive drugs and related tumor risks that have helped to move the field forward from associative to causative conclusions, in hope of providing a reference for more rigorous and evidence-based clinical research on the topic to guide the clinical decision making.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: